Effective anti-tuberculosis therapy correlates with plasma small RNA

Eur Respir J. 2015 Jun;45(6):1741-4. doi: 10.1183/09031936.00221214. Epub 2015 Mar 5.

Authors

Isobella Honeyborne¹, Marc C Lipman², Clare Eckold³, Dimitrios Evangelopoulos³, Stephen H Gillespie⁴, Alexander Pym⁵, Timothy D McHugh³

Affiliations

¹ Centre for Clinical Microbiology, Dept of Infection, University College London, London, UK i.honeyborne@ucl.ac.uk.
² Centre for Respiratory Medicine, University College London, London, UK.
³ Centre for Clinical Microbiology, Dept of Infection, University College London, London, UK.
⁴ School of Medicine, Medical and Biological Sciences, University of St Andrews, St Andrews, UK.
⁵ K-RITH (KwaZulu-Natal Research Institute for Tuberculosis and HIV), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.

PMID: 25745052
DOI: 10.1183/09031936.00221214

No abstract available

Publication types

Clinical Study
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antitubercular Agents / therapeutic use*
Biomarkers / blood
Coinfection
Ethambutol / therapeutic use
Female
Gene Expression Profiling
HIV Infections / complications
Humans
Isoniazid / therapeutic use
Male
MicroRNAs / blood
Prospective Studies
Pyrazinamide / therapeutic use
RNA / blood*
Rifampin / therapeutic use
Treatment Outcome
Tuberculosis, Pulmonary / complications
Tuberculosis, Pulmonary / drug therapy*
Tuberculosis, Pulmonary / genetics

Substances

Antitubercular Agents
Biomarkers
MicroRNAs
Pyrazinamide
RNA
Ethambutol
Isoniazid
Rifampin

Grants and funding

G0601466/Medical Research Council/United Kingdom